Published in Cancer Treat Rev on July 18, 2011
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Ovarian carcinoma: quantitative biexponential MR imaging relaxometry reveals the dynamic recruitment of ferritin-expressing fibroblasts to the angiogenic rim of tumors. Radiology (2013) 1.51
Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med (2013) 1.03
New developments in the treatment of ovarian cancer--future perspectives. Ann Oncol (2013) 0.86
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med (2016) 0.85
Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clin Cancer Res (2014) 0.85
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Womens Health (2016) 0.85
Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev (2014) 0.83
Biomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies. BMC Syst Biol (2012) 0.82
Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer. BMC Cancer (2014) 0.82
Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression. Oncogene (2015) 0.76
The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis. Sci Rep (2016) 0.75
Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization. Oncogene (2017) 0.75
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med (2012) 5.31
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res (2002) 3.64
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res (2009) 1.39
Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res (2007) 1.29
Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis (2008) 1.24
Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem (2009) 1.14
Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol (2009) 1.06
TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics (2014) 0.99
PDGF induced microRNA alterations in cancer cells. Nucleic Acids Res (2011) 0.97
Tissue transglutaminase regulates β-catenin signaling through a c-Src-dependent mechanism. FASEB J (2013) 0.91
Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase. Mol Cancer Ther (2011) 0.89
Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer. Neoplasia (2013) 0.88
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer (2013) 0.84
Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer: a meta-analysis. Cancer (2010) 0.82
Bleeding Dieulafoy's-like lesions of the gut identified by capsule endoscopy. World J Gastroenterol (2013) 0.80
Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Mol Cancer Ther (2012) 0.79
Pegylated liposomal doxorubicin in ovarian cancer. Ther Clin Risk Manag (2009) 0.78
Blockade of FGF signaling: therapeutic promise for ovarian cancer. Cancer Biol Ther (2010) 0.77
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer (2012) 0.77
A multidisciplinary approach in patients with femoral neck fracture on an osteoporotic basis. Rom J Morphol Embryol (2010) 0.76
Global DNA methylation profiling technologies and the ovarian cancer methylome. Methods Mol Biol (2015) 0.76
Evaluation of cardiac parameters using electrical impedance plethysmography. Rev Med Chir Soc Med Nat Iasi (2012) 0.75
Breast mass in a patient with ovarian cancer: a case report. J Reprod Med (2009) 0.75
Accidentally ingested foreign body associated with liver actinomycosis: the diagnostic value of imaging. J Gastrointestin Liver Dis (2013) 0.75